Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden, Sweden
SOBI (Employment)
OP-25B - Cardiovascular Risk in Users of Mirabegron Relative to Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-interventional, Real-world Data Safety Study
Tuesday, August 24, 20211:45 PM – 3:30 PM US Eastern Time